Sanofi to acquire Provention Bio and type 1 diabetes drug
The US-based company’s Tzield is the only approved treatment in the US to delay the onset of late-stage type 1 diabetes.
by marketwire, translated by daniel pedersen
French pharmaceutical company Sanofi have struck a deal to acquire US-based Provention Bio and its type 1 diabetes therapy, Tzield.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Scientists discover flaw in insulin absorption assumption
For subscribers
.jpg&w=384&q=75)
